Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyverna Therapeutics, Inc. (KYTX : NSDQ)

• Company Description    Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $7.41 Daily Weekly Monthly 20 Day Moving Average: 1,433,947 shares Shares Outstanding: 60.79 (millions) Market Capitalization: $450.49 (millions) Beta: 1.87 52 Week High: $13.67 52 Week Low: $2.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.63% -10.30% 12 Week -15.80% -18.10% Year To Date -21.17% -28.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 HORTON STREET SUITE 550 - EMERYVILLE,CA 94608 USA ph: 510-626-8331 fax: - investorrelations@kyvernatx.com https://kyvernatx.com

• General Corporate Information    Officers Warner Biddle - Chief Executive Officer and Director Christi Shaw - Executive Chairperson and Director Marc Grasso - Chief Financial Officer Fred E. Cohen - Director Sravan Emany - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501976104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 60.79 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $450.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.92% vs. Previous Quarter: 17.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -81.88 12/31/25 - -81.47 ROA 06/30/26 - - 03/31/26 - -64.87 12/31/25 - -66.70 Current Ratio 06/30/26 - - 03/31/26 - 8.15 12/31/25 - 7.75 Quick Ratio 06/30/26 - - 03/31/26 - 8.15 12/31/25 - 7.75 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 3.23 12/31/25 - 3.85 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.13 12/31/25 - 0.11 Debt-to-Capital 06/30/26 - - 03/31/26 - 11.26 12/31/25 - 9.63

Powered by Zacks Investment Research ©